PEARL Extension Data and What Happened After the Trial Ended
Deep dive into the PEARL trial's follow-up and extension findings for weekly rapamycin in healthy adults, covering durability of effects, safety signals, and long-term outcome data.
3 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 3 of 3 clinical reviews.
Deep dive into the PEARL trial's follow-up and extension findings for weekly rapamycin in healthy adults, covering durability of effects, safety signals, and long-term outcome data.
PEARL tested weekly rapamycin in older adults over 48 weeks, showing modest quality-of-life gains and no major safety issues, but no updated guidelines yet.
A detailed breakdown of the PEARL trial's rapamycin results in healthy older adults, including effect sizes, secondary endpoints, immune markers, and time-course patterns from this landmark 2024 Aging Cell RCT.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.